Grifols (GRFS) Depreciation and Depletion (2010 - 2016)
Grifols' (GRFS) quarterly Depreciation and Depletion came in at $55.6 million in Q3 2016, up 2.76% YoY from $54.1 million in Q4 2015, and little changed on a QoQ basis from $55.8 million in Q4 2015.
Grifols (GRFS) Depreciation and Depletion (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Depreciation and Depletion data on file, last reported at $55.6 million in Q3 2016.
- Quarterly Depreciation and Depletion rose 2.76% year-over-year to $55.6 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $217.0 million (down 0.69% YoY) and the FY2015 annual result came in at $210.8 million, down 16.31% from the prior year.
- Depreciation and Depletion was little changed at $55.6 million in Q3 2016, from $55.8 million in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $183.8 million in Q3 2014 to a low of -$63.5 million in Q2 2014.
- A 5-year average of $50.0 million and a median of $43.5 million in 2013 frame the typical range for Depreciation and Depletion.
- The widest YoY moves for Depreciation and Depletion: up 329.0% in 2014, down 246.5% in 2014.
- Tracing GRFS's Depreciation and Depletion over 5 years: stood at $41.2 million in 2012, then climbed by 5.4% to $43.5 million in 2013, then soared by 46.47% to $63.7 million in 2014, then decreased by 12.28% to $55.8 million in 2015, then declined by 0.38% to $55.6 million in 2016.
- The last three Depreciation and Depletion figures came in at $55.6 million (Q3 2016), $55.8 million (Q4 2015), and $54.1 million (Q3 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 55.63 Mn |
| Sep 30, 2016 | 55.63 Mn |
| Dec 31, 2015 | 55.85 Mn |
| Dec 31, 2015 | 55.85 Mn |
| Sep 30, 2015 | 54.14 Mn |
| Sep 30, 2015 | 54.14 Mn |
| Jun 30, 2015 | 51.35 Mn |
| Jun 30, 2015 | 51.35 Mn |
| Mar 31, 2015 | 49.33 Mn |
| Mar 31, 2015 | 49.33 Mn |
| Dec 31, 2014 | 63.66 Mn |
| Dec 31, 2014 | 63.66 Mn |
| Sep 30, 2014 | 183.76 Mn |
| Sep 30, 2014 | 183.76 Mn |
| Jun 30, 2014 | -63.47 Mn |
| Jun 30, 2014 | -63.47 Mn |
| Mar 31, 2014 | 63.52 Mn |
| Mar 31, 2014 | 63.52 Mn |
| Dec 31, 2013 | 43.47 Mn |
| Dec 31, 2013 | 43.47 Mn |